Calmare Therapeutics Inc (fka CTTC)

[powderbum]

This speaks for itself

http://abstract.asco.org/AbstView_114_96734.html
Abstract Sub-category: Symptom Management/Supportive Care/Palliative Care
Category: Patient and Survivor Care
Meeting: 2012 ASCO Annual Meetingtract No: e19564^
Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2012 Annual
Meeting but not presented at the Meeting, can be found online only. The publication-only abstracts are not included in
the print or USB versions of the ASCO Annual Meeting Proceedings Part I, but they are citable to the Journal of Clinical
Oncology as a supplement
Citation: J Clin Oncol 30, 2012 (suppl; abstr e19564^)
Author(s): Thomas J. Smith, Giuseppe Marineo; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Baltimore, MD; Delta Research and Development, Centro Ricerche Bioingegneria Medica-University of Rome "Tor
Vergata", Rome, Italy
Abstract:
Background: Post herpetic neuropathy (PHN) is common in cancer and hematologic malignancy patients. It can be
debilitating and difficult to treat effectively. Scrambler therapy, a patient-specific neurocutaneous stimulation device,
can be effective in treating chemotherapy induced neuropathy (JPSM 2010) and other neuropathic pain (JPSM 2012).
Methods: We treated ten patients, 2 with cancer as their primary diagnosis, with refractory PHN Scrambler therapy at
two institutions. Scrambler therapy was given as 30 minute sessions daily for 10 days. Pain was recorded before and
after treatment.
Results: The patient mean age was 54 ± SD 13 years, 6 men and 4 women, with a mean duration of PHN for 15.6 months
(range 2.5 to 48 months) without satisfactory relief despite conventional drugs. The average pain score rapidly
diminished from 7.64 ± 1.46 at baseline to 0.42 ± 0.89 at one month, a 95% reduction, with continued relief at 2 and 3
months. Patients achieved maximum pain relief with less than 5 treatments.
Conclusions: Scrambler therapy appears to have a promising effect on PHN, with prompt and continued relief and no
side effects. Further research is warranted.
Time Pain scores (0-10)
Baseline 7.64
Month 1 0.42
Month 2 1.93
Month 3 2.21
Abstract Disclosures: The following represents disclosure information provided by authors of this abstract. The ASCO Scientific
Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented
strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless
otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L =
Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member
Thomas J. Smith - No relevant relationships to disclose


Dr. Smith will blow the roof off with this next study.